Vizient, a healthcare performance improvement company, recently released its Drug Price Forecast Highlights biannual report that provides an estimate of the change in the cost of medicines for 2019.
Vizient, a healthcare performance improvement company, recently released its Drug Price Forecast Highlights biannual report that provides an estimate of the change in the cost of medicines for 2019.
The projected inflation rate, which is weighted by Vizient member purchases and covers all classes of trade with the exception of 340B purchases, is projected to be 4.92%. This is a slower rate of growth compared with previous Vizient forecasts, such as 7.61% that was projected for 2018.
Over the time period studied, the highest spending based on therapeutic classes was seen in disease-modifying antirheumatic agents (DMARDs) for the treatment of rheumatoid arthritis. This class includes key products such as adalimumab, etanercept, and infliximab; all products for which biosimilars have been developed and FDA-approved, however not all are available on the market today.
“Where we need competition the most is in 2 areas: one, [for] drugs that have never had competition; drugs that have been going on for decades without competition. The second area is of high cost drugs. Well, [adalimumab, etanercept, and infliximab] meet both criteria. They have a strong grip on the entire marketplace, and they’re really expensive. That’s what gets us so excited about biosimilars,” said Dan Kistner, PharmD, senior vice president of pharmacy solutions at Vizient in an interview with The Center for Biosimilars®.
In fact, in rheumatoid arthritis, specifically, the report projects an 8.57% increase in the cost of the top 5 branded products in 2019: infliximab, adalimumab, etanercept, abatacept, and certolizumab.
“When you look at the [rheumatoid arthritis] market today, the uptake of biosimilars is 3%. It’s just not good enough to make a dent,” said Kistner. When asked if he thought the recent release of the Biosimilar Action Plan would help increase the market share of biosimilars, he said, “Anything that’s going to help those products come to market faster or fight current hurdles that they have—whether that be with reimbursement or therapeutic uptake– we fully support it.”
Competition fuels everything, said Kistner. In looking to address the drug pricing problem in America that has garnered a lot of media attention as of late, Kistner said that the answer could lie in biosimilars creating more competition in the market. “We have a solution to lower drug pricing in this country on the drugs that are the top 10 [most expensive] drugs for the country: it’s biosimilars. We’ve got to do everything we can to make sure that we’re limiting any risk or speed bumps in the road in getting them to market.”
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.